Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL 30 mg tablets throughout…
Indero Marks 25 Years of Innovation in Clinical Research and Looks Ahead to a New Era in Dermatology and Rheumatology Indero, the specialized contract research organization (CRO) formerly known as Innovaderm, has reached an important milestone in its journey—25 years…
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the eighth annual Cytokinetics Communications Grant Program. The program will award five grants to patient advocacy organizations…
European Commission Grants Approval for Henlius and Organon’s Denosumab Biosimilars BILDYOS® and BILPREVDA® Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a significant regulatory milestone with the news that the European Commission (EC) has granted marketing authorization for…
MindMed Presents Alarming Data on Suicidal Ideation Among Adults with Generalized Anxiety Disorder at Psych Congress 2025 Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company pioneering the development of novel product candidates for brain health…
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025 Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress,…
In New DTC Ad Crackdown, FDA Trying to Close a Loophole That Isn’t While the FDA is trumpeting this new initiative as “sweeping reforms” to the way drug companies can advertise, experts say the regulator is going after a problem…
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due…
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior…
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cat Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
WuXi Biologics Achieves “CDMO of the Year” Among Three Prestigious IMAPAC Awards WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the “CDMO of the Year – Asia Pacific”, “Best Biologics…
QIAGEN Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Expands Diagnostic Leadership with Enhanced Meningitis/Encephalitis Panel QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a significant regulatory milestone: the company has secured CE-IVDR certification for its entire QIAstat-Dx syndromic…